Interesting article and observations in * today. I was...

Interesting article and observations in * today. I was aware of cuv but never caught my attention due to the price trend. Following up more after reading this article it seems they are experiencing something similar to neu but have been experiencing it since 2021. Both seem to be head scratches from a shareprice performance perspective. Like neu, they are generating revenue and growing profitably, plenty of cash, have drugs in the pipeline, consensus analyst valuation more than twice current shareprice, and lots of talk about how they're so undervalued and that a take over is just around the corner.

admittedly this is what I gained after a very quick read, so those familiar with cuv, is there anything different from a shareprice performance and catalyst pov that would differentiate the two or are the similar price trends just reflecting the macro and market environment we're in? I tend to think maybe the later, so if we get a turn, then maybe both will do well.

https://**promotion blocked**/health/health-check-local-biotech-starred-in-2024-but-the-rising-tide-did-not-lift-all-boats/?utm_medium=email&utm_campaign=Lunchtime%20-01-01-2025&utm_content=httpsstockheadcomauhealthhealthchecklocalbiotechstarredin2024buttherisingtidedidnotliftallboats&utm_medium=email&utm_campaign=Lunch%20Jan%202&utm_content=Lunch%20Jan%202+CID_36d95891757f176af3a3474f94911eab&utm_source=Campaign%20Monitor&utm_term=Health%20Check%20Local%20biotech%20starred%20in%202024%20but%20the%20rising%20tide%20did%20not%20lift%20all%20boats